Fragment-based discovery of 6-azaindazoles as inhibitors of bacterial DNA ligase

ACS Medicinal Chemistry Letters

Volumn 4, Issue 12, 2013, Pages 1208-1212

  Howard, Steven ^a   Amin, Nader ^a   Benowitz, Andrew B ^b   Chiarparin, Elisabetta ^a   Cui, Haifeng ^b   Deng, Xiaodong ^b   Heightman, Tom D ^a   Holmes, David J ^b   Hopkins, Anna ^a   Huang, Jianzhong ^b   Jin, Qi ^b   Kreatsoulas, Constantine ^b   Martin, Agnes C L ^a   Massey, Frances ^a   McCloskey, Lynn ^b   Mortenson, Paul N ^a   Pathuri, Puja ^a   Tisi, Dominic ^a   Williams, Pamela A ^a  

^a ASTEX PHARMACEUTICALS   (United Kingdom)

^b GLAXOSMITHKLINE   (United States)

Author keywords

Bacterial DNA ligase; fragment based drug design; S. aureus; structure based optimization

Indexed keywords

6 AZAINDAZOLE; ANTIINFECTIVE AGENT; BACTERIAL DNA; INDAZOLE DERIVATIVE; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; CROSS RESISTANCE; CRYSTAL STRUCTURE; DRUG DESIGN; IC 50; MINIMUM BACTERICIDAL CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; X RAY CRYSTALLOGRAPHY;

EID: 84890455263     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml4003277     Document Type: Article

References (21)

1. Shuman, S. J. DNA ligases: Progress and prospects J. Biol. Chem. 2009, 284, 17365
2. Lehman, I. R. DNA ligase: Structure, mechanism and function Science 1974, 186, 790
3. Tomkinson, A. E.; Vijayakumar, S.; Pascal, J. M.; Ellenberger, T. DNA ligase: Structure, reaction mechanism and function Chem. Rev. 2006, 106, 687
4. Streker, K.; Schäfer, T.; Freiberg, C.; Brötz-Oesterhelt, H.; Hacker, J.; Labischinski, H.; Ohlsen, K. In vitro and in vivo validation of ligA and tarI as essential targets in Staphylococcus aureus Antimicrob. Agents Chemother. 2008, 52, 4470-4474
5. Lavesa-Curto, M.; Sayer, H.; Bullard, D.; MacDonald, A.; Wilkinson, A.; Smith, A.; Bowater, L.; Hemmings, A.; Bowater, R. P. Characterisation of a temperature-sensitive DNA ligase from Escherichia coli Microbiology 2004, 150, 4171-4180
6. Swift, R. V.; Amaro, R. M. Discovery and design of DNA and RNA ligase inhibitors in infectious microorganisms Expert Opin. Drug Discovry 2009, 4, 1281-1294
7. Boucher, H. W.; Talbot, G. H.; Bradley, J. S.; Edwards, J. E.; Gilbert, D.; Rice, L. B.; Scheld, M.; Spellberg, B.; Bartlett, J. Bad bugs, no drugs: No ESKAPE! An update from the Infectious Diseases Society of America Clin. Infect. Dis. 2009, 48, 1
8. +-dependent DNA ligase inhibitors with broad-spectrum activity and antibacterial efficacy in vivo Antimicrob. Agents Chemother. 2011, 1088, 55
9. +-dependent DNA ligase inhibitors: Optimization of antibacterial activity Bioorg. Med. Chem. Lett. 2011, 21, 4556
10. Surivet, J.-P.; Lange, R.; Hubschwerlen, C.; Keck, W.; Specklin, J.-L.; Ritz, D.; Bur, D.; Locher, H.; Seiler, P.; Strasser, D. S.; Prade, L.; Kohl, C.; Schmitt, C.; Chapoux, G.; Ilhan, E.; Ekambaram, N.; Athanasiou, A.; Knezevic, A.; Sabato, D.; Chambovey, A.; Gaertner, M.; Enderlin, M.; Boehme, M.; Sippel, V.; Wyss, P. Structure-guided design, synthesis and biological evaluation of novel DNA ligase inhibitors with in vitro and in vivo anti-staphylococcal activity Bioorg. Med. Chem. Lett. 2012, 22, 6705-6711
11. +-dependent DNA ligase inhibitors as potential antibacterial agents. Part II: 4-amino-pyrido[2,3-d]pyrimidin-5(8H)-ones Bioorg. Med. Chem. Lett. 2012, 22, 3699-3703
12. Payne, D. J.; Gwynn, M. N.; Holmes, D. J.; Pompliano, D. L. Drugs for bad bugs: Confronting the challenges of antibacterial discovery Nat. Rev. Drug Discovery 2007, 6 (1) 29-40
13. Murray, C. W.; Rees, D. C. The rise of fragment-based drug discovery Nat. Chem. 2009, 1, 187-192
14. Eakin, A. E.; Green, O.; Hales, N.; Walkup, G. K.; Bist, S.; Singh, A.; Mullen, G.; Bryant, J.; Embrey, K.; Gao, N.; Breeze, A.; Timms, D.; Andrews, B.; Uria-Nickelsen, M.; Demeritt, J.; Loch, J. T., III; Hull, K.; Blodgett, A.; Illingworth, R. N.; Prince, B.; Boriack-Sjodin, P. A.; Hauck, S.; MacPherson, L. J.; Ni, H.; Sherer, B. Pyrrolamide DNA gyrase inhibitors: Fragment-based NMR screening to antibacterial agents Antimicrob. Agents Chemother. 2012, 56 (3) 1240-1246
15. Hudson, S. A.; McLean, K. J.; Surade, S.; Yang, Y. Q.; Leys, D.; Ciulli, A.; Munro, A. W.; Abell, C. Application of fragment screening and merging to the discovery of inhibitors of the mycobacterium tuberculosis cytochrome P450 CYP121 Angew. Chem., Int. Ed. 2012, 51, 9311-9316
16. Murray, C. W.; Verdonk, M. L.; Rees, D. C. Experiences of fragment-based drug discovery Trends Pharmacol. Sci. 2012, 33 (5) 224-232
17. O'Shea, R.; Moser, H. E. Physicochemical properties of antibacterial compounds: Implications for drug discovery J. Med. Chem. 2008, 51, 2871-2878
18. Manchester, J. I.; Buurman, E. T.; Bisacchi, G. S.; McLaughlin, R. E. Molecular determinants of AcrB-mediated bacterial efflux implications for drug discovery J. Med. Chem. 2012, 55, 2532-2537
19. 50)/ HAC. Hopkins, A. L.; Groom, C. R.; Alex, A. Ligand efficiency: A useful metric for lead selection Drug Discovery Today 2004, 9, 430-431
20. +-dependent DNA ligase from Staphylococcus aureus Acta Crystallogr. 2009, F65, 1078-1082
21. Mortenson, P. N.; Murray, C. W. J. Comput. Aided Mol. Des. 2011, 25, 663-667